Akebia Therapeutics reports Q3 2026 revenue of $36.9 M and a net loss of $14.35 M
Akebia Therapeutics announced third‑quarter 2026 results. Total revenue fell 37% year‑over‑year to $36.9 million, while a net loss of $14.35 million was recorded. Vafseo (vadadustat) generated $14.8 million in product revenue and was used by about 11,500 patients, a 140% increase from the prior year. The company highlighted positive VOICE trial data showing a 10% reduction in hospitalizations versus ESA and said cash and cash equivalents stood at $159.3 million.
Why it matters
The sharp revenue decline and loss signal short‑term earnings pressure for investors, while the strong cash position should fund operations for at least two years. Positive trial results could support future Vafseo adoption and revenue growth, which analysts may view as a longer‑term upside.
Key facts
- 1Total third‑quarter revenue was $36.9 million, down 37% from $58.8 million a year earlier. tradingview.com
- 2Net loss for the quarter was $14.35 million. tradingview.com
- 3Vafseo net product revenue was $14.8 million. stocktitan.net
- 4Approximately 11,500 patients were on Vafseo at quarter end, up about 140% YoY. stocktitan.net
- 5Cash and cash equivalents totaled $159.3 million at quarter end. stocktitan.net
- 6Auryxia net product revenue declined to $20.0 million from $42.5 million a year earlier. tradingview.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.